SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Insulin | Pancragen | Erythropoietin / EPO |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Glucose-regulating hormone / product-specific medicine family | KEDW tetrapeptide / pancreatic research | Erythropoiesis-stimulating hormone / medicine family |
| PrimeCore Class | Class AApproved in a bounded context | Class CExperimental / limited evidence | Class AApproved in a bounded context |
| Evidence Grade | Grade AStrong regulatory + clinical evidence | Grade DLimited / observational evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Insulin medicines are essential in defined diabetes settings but can cause life-threatening hypoglycaemia. Human insulin, analogues and premixes differ. A catalogue entry without the exact type, formulation and device cannot identify an authorised medicine or support product switching or bodybuilding use. | Pancragen is KEDW, with terminal-form details requiring verification. A limited report included 30 healthy older adults and 33 people with type 2 diabetes; its abstract does not establish a randomised 63-person treatment trial. Biomarker and cell-differentiation findings do not justify replacing insulin or standard diabetes care. | EPO is an erythropoietic hormone and an ambiguous catalogue label, not a verified product identity. Authorised epoetin medicines treat selected anaemias, with risks including hypertension and thrombosis. Specific ESA warnings include stroke, cardiovascular events and tumour progression in defined settings. No endurance-enhancement recommendation is made. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations | English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions